bullish
Lianbio -Ads (LIAN) - Tuesday, Oct 31, 2023
SUMMARY
Key points (machine generated)
- LianBio is winding down its portfolio of in-licensed drug candidates and returning cash to shareholders.
- The company recently sold exclusive rights to develop and commercialize mavacamten in certain areas of Asia to Bristol Myers Squibb for $350 million.
- LianBio will have approximately $600 million in net cash after the transaction, exceeding its current market capitalization of around $434 million. A strategic review is ongoing, and it is expected that the company will wind down its business and distribute cash to shareholders, potentially leading to a higher share price reflecting its cash holdings.
This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x